[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. 2013

Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada

Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer. Capecitabine-containing chemotherapy is recommended as a first-line option for gastrointestinal tract cancer. The incidence of hand-foot syndrome (HFS), an adverse event of chemotherapy with capecitabine, is high. Moreover, once the symptoms of HFS are identified, they can significantly impair the quality of life (QOL) of patients. HFS should be managed by dose interruption and, if necessary, by dose reduction. Pharmacists and oncology nurses play an increasingly important role in the early identification and prevention of HFS through patient education and close clinical assessment. The aim of this study was to evaluate the efficacy of support tools for the early identification, prevention, and management of HFS and to assess the effectiveness of "patient self-check sheets". The patient was detected as having HFS of mild severity and had used a moisturizer at the time of initiation of therapy. Maintaining moisture retention is important in the management of HFS. The ambulatory team plays a key role by using self-check sheets to educate patients on how to recognize HFS, when to interrupt treatment, and how to adjust the dose so as to maintain effective therapy with capecitabine. For the continuation and completion of treatment and for maintaining an improved QOL in the home environment, supportive measures for adverse effects such as HFS and an ambulatory team are indispensable.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069287 Capecitabine A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER. N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine,Xeloda
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D060831 Hand-Foot Syndrome Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies. Chemotherapy-Induced Acral Erythema,Chemotherapy-Induced Palmoplantar Erythrodysesthesia,Acral Erythema, Chemotherapy-Induced,Acral Erythemas, Chemotherapy-Induced,Chemotherapy Induced Acral Erythema,Chemotherapy Induced Palmoplantar Erythrodysesthesia,Chemotherapy-Induced Acral Erythemas,Chemotherapy-Induced Palmoplantar Erythrodysesthesias,Hand Foot Syndrome,Hand-Foot Syndromes,Palmoplantar Erythrodysesthesia, Chemotherapy-Induced,Palmoplantar Erythrodysesthesias, Chemotherapy-Induced,Syndrome, Hand-Foot,Syndromes, Hand-Foot

Related Publications

Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
October 2004, Journal of clinical pharmacology,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
January 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
October 2018, Chemical research in toxicology,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
August 2008, Gan to kagaku ryoho. Cancer & chemotherapy,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
September 2010, Gan to kagaku ryoho. Cancer & chemotherapy,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
January 2024, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
April 2024, Cureus,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
June 2007, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
January 2002, Cancer investigation,
Kouhei Yamagiwa, and Tadashi Shigematsu, and Keiko Takeda, and Masahiro Shirai, and Keiko Amemori, and Kazumi Sunda, and Chikayo Koike, and Toshimi Yamada
March 2011, Expert opinion on drug safety,
Copied contents to your clipboard!